AB Science S.A (AB) - Total Assets
Based on the latest financial reports, AB Science S.A (AB) holds total assets worth €21.22 Million EUR (≈ $24.80 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AB operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
AB Science S.A - Total Assets Trend (2009–2024)
This chart illustrates how AB Science S.A's total assets have evolved over time, based on quarterly financial data. See AB total equity for net asset value and shareholders' equity analysis.
AB Science S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
AB Science S.A's total assets of €21.22 Million consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.5% |
| Accounts Receivable | €827.00K | 3.6% |
| Inventory | €184.00K | 0.8% |
| Property, Plant & Equipment | €899.00K | 3.9% |
| Intangible Assets | €1.33 Million | 5.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how AB Science S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AB Science S.A market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AB Science S.A's current assets represent 62.7% of total assets in 2024, a decrease from 93.2% in 2009.
- Cash Position: Cash and equivalents constituted 34.5% of total assets in 2024, up from 12.7% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, unchanged from 5.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 5.7% of total assets.
AB Science S.A Competitors by Total Assets
Key competitors of AB Science S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
AB Science S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.82 | 0.79 |
| Quick Ratio | 0.67 | 0.80 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-6.07 Million | €-3.15 Million | €-4.96 Million |
AB Science S.A - Advanced Valuation Insights
This section examines the relationship between AB Science S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.81 |
| Asset Growth Rate (YoY) | -9.1% |
| Total Assets | €23.18 Million |
| Market Capitalization | $41.86 Million USD |
Valuation Analysis
Above Book Valuation: The market values AB Science S.A's assets above their book value (1.81x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: AB Science S.A's assets decreased by 9.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AB Science S.A (2009–2024)
The table below shows the annual total assets of AB Science S.A from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €23.18 Million ≈ $27.09 Million |
-9.11% |
| 2023-12-31 | €25.50 Million ≈ $29.81 Million |
+6.95% |
| 2022-12-31 | €23.84 Million ≈ $27.87 Million |
+12.08% |
| 2021-12-31 | €21.27 Million ≈ $24.87 Million |
-28.35% |
| 2020-12-31 | €29.69 Million ≈ $34.71 Million |
+67.35% |
| 2019-12-31 | €17.74 Million ≈ $20.74 Million |
-21.12% |
| 2018-12-31 | €22.49 Million ≈ $26.29 Million |
-55.55% |
| 2017-12-31 | €50.60 Million ≈ $59.16 Million |
+33.12% |
| 2016-12-31 | €38.01 Million ≈ $44.44 Million |
+16.67% |
| 2015-12-31 | €32.58 Million ≈ $38.09 Million |
+4.16% |
| 2014-12-31 | €31.28 Million ≈ $36.56 Million |
-28.32% |
| 2013-12-31 | €43.63 Million ≈ $51.01 Million |
+45.53% |
| 2012-12-31 | €29.98 Million ≈ $35.05 Million |
+1.76% |
| 2011-12-31 | €29.46 Million ≈ $34.44 Million |
+0.22% |
| 2010-12-31 | €29.40 Million ≈ $34.37 Million |
+108.70% |
| 2009-12-31 | €14.09 Million ≈ $16.47 Million |
-- |
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more